Development of Secondary Cancers in Pre- vs Post-ICI Eligibility Periods for Metastatic Cancers | Synapse
February 6, 2026Open Access
Development of Secondary Cancers in Pre- vs Post-ICI Eligibility Periods for Metastatic Cancers
Key Points
This study examines the incidence of secondary primary cancers related to the use of immune checkpoint inhibitors.
Cohort study design
Comparison of cancer incidence before and after ICI approval
Assessment of metastatic cancer patients
Increased incidence of secondary cancers observed after ICI approval
Variation in types of secondary cancers identified pre- and post-ICI
Potential implications for cancer management strategies.
Abstract
This cohort study investigates incidence of secondary primary cancers before vs after approval of immune checkpoint inhibitors (ICIs) among patients with metastatic cancers.